NASDAQ: TELA - TELA Bio, Inc.

Yield per half year: -60.58%
Dividend yield: 0.00%
Sector: Healthcare

Share chart TELA Bio, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About TELA Bio, Inc.

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy.

more details
The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2019-11-08
ISIN US8723811084
Industry Health Care Equipment & Supplies
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.telabio.com
Цена ао 1.29
Change price per day: +1.49% (1.01)
Change price per week: +10.22% (0.93)
Change price per month: -56.38% (2.35)
Change price per 3 month: -62.59% (2.74)
Change price per half year: -60.58% (2.6)
Change price per year: -79.38% (4.97)
Change price per 3 year: -90.5% (10.79)
Change price per 5 year: -80.98% (5.39)
Change price per year to date: -63.39% (2.8)
All parameters

Underestimation

Title Value Grade
P/S 2.55 6
P/BV 7.9 1
P/E 0 0
EV/EBITDA -3.35 0
Total: 4.63

Efficiency

Title Value Grade
ROA, % -59.79 0
ROE, % -247.15 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.9495 10
Total: 8.6

Growth impulse

Title Value Grade
Yield Revenue, % 279.56 10
Yield Ebitda, % 116.13 10
Yield EPS, % -86.03 0
Total: 7
More

Institutions Volume Share, %
Essex Woodlands Management Inc. 4110709 16.68
Orbimed Advisors LLC. 2835542 11.5
First Light Asset Management, LLC 2554641 10.36
Nantahala Capital Management, LLC 2195732 8.91
AIGH Capital Management LLC 1377945 5.59
Blackrock Inc. 1078056 4.37
Vanguard Group Inc 998853 4.05
Pentwater Capital Management LP 990000 4.02
SILVERARC CAPITAL MANAGEMENT, LLC 795080 3.23
Federated Hermes, Inc. 712300 2.89

ETFShare, %Profitability for 1 year, %Dividends, %
Jacob Forward ETF 2.05852 43.03 0.15284
2.0643.030.15



Head Job title Payment Year of birth
Mr. Antony Koblish Co-founder, President, CEO & Director 1.03M 1966 (59 years)
Mr. Roberto E. Cuca J.D. CFO & COO 674.78k 1968 (57 years)
Mr. Paul Talmo Chief Technology Officer 595.67k 1972 (53 years)
Ms. Megan Smeykal VP, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer N/A 1976 (49 years)
Mr. D. Taylor Ocasio General Counsel & Corporate Secretary N/A
Ms. Jennifer Lou Armstrong Senior Vice President of Human Resources N/A 1970 (55 years)
Mr. Gregory A. Firestone Chief Commercial Officer N/A 1959 (66 years)
Mr. Michael Leonard Senior Vice President of Technical Operations N/A
Mr. Peter C. Murphy Chief Commercial Officer 542.34k 1973 (52 years)
Louisa Smith Investor Relations Contact Officer N/A

Address: United States, Malvern. PA, 1 Great Valley Parkway - open in Google maps, open in Yandex maps
Website: https://www.telabio.com